N6-methyladenosine-modified SRD5A3, identified by IGF2BP3, sustains cisplatin resistance in bladder cancer
Kai Liao, Jing Li, Caixian He, Jiyong Peng · 2024
Read N6-methyladenosine-modified SRD5A3, identified by IGF2BP3, sustains cisplatin resistance in bladder cancer by Kai Liao, Jing Li, Caixian He, Jiyong Peng (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11649775.txt.
Description
Kai Liao and co-authors published a study in 2024 on a gene that helps bladder cancer resist the drug cisplatin. Resistance limits how much patients gain from this standard therapy. A chemical mark on RNA, read by a protein called IGF2BP3, drew the team's focus. They found the gene SRD5A3 raised in tumors and even more in drug-resistant cancer cells.
Silencing either the gene or its reader protein slowed growth and restored drug sensitivity in resistant cells. Tests showed the reader spots the mark on the gene's RNA and keeps it stable. In mice, silencing either partner curbed tumor growth under drug treatment. The authors name the pair as rational targets.
Catalog record
| CREATOR | Kai Liao, Jing Li, Caixian He, Jiyong Peng |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |